<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00957528</url>
  </required_header>
  <id_info>
    <org_study_id>01-302</org_study_id>
    <secondary_id>GCRC 615</secondary_id>
    <secondary_id>R01AG022023</secondary_id>
    <nct_id>NCT00957528</nct_id>
  </id_info>
  <brief_title>Cycled Testosterone Replacement Study</brief_title>
  <official_title>The Effects of Cyclic Testosterone Administration on Muscle Function in Older Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether testosterone (male hormone) therapy is
      effective if administered in a cyclic fashion (periodic dosing) compared to continuous dosing
      in men aged 60 to 85 years. Effectiveness will be determined based on improvements in body
      composition, muscle metabolism, muscle strength, and bone metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men and women undergo a progressive reduction in lean muscle mass (sarcopenia) with advancing
      age regardless of their level of physical activity. A 12-yr longitudinal study in healthy
      sedentary older men showed a correlation between loss of muscle cross-sectional area and
      muscle strength of the thigh, quadriceps, and flexor muscles. Once weakened, older
      individuals are prone to falls that prevent independent living and diminish the quality of
      life. There is a need to develop therapies to counteract losses in skeletal muscle strength
      with aging. Studies show that exercise and testosterone administration increase skeletal
      muscle mass and strength in older men. However, the increase in muscle strength by
      testosterone in older men has not been consistent in all studies. Androgens increase muscle
      mass by either increasing muscle protein synthesis or inhibiting muscle protein breakdown.
      This proposal will investigate the hypothesis that cyclic testosterone administration
      (monthly on/off cycles) will preferentially increase muscle protein synthesis and result in a
      consistent and greater improvement in muscle strength than continuous testosterone
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months</measure>
    <time_frame>5 Months</time_frame>
    <description>The fractional synthetic rate (FSR) of mixed muscle is calculated by directly measuring the incorporation of L-[ring-13C6]-phenylalanine into protein (%/hr),, using the precursor-product model: FSR = [(EP2 − EP1)/(EM•t)]•60•100, where EP1 and EP2 are the enrichments of bound L-[ring-13C6]-phenylalanine in the first and second muscle biopsies, t is the time interval (min) between biopsies, and EM is the mean L-[ring-13C6]-phenylalanine enrichment in the muscle intracellular pool.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Muscle Strength as Measured by Maximal Voluntary Contraction Tests (Arm Curl) at Baseline, One Month, Two Months, Three Months, Four Months, and at Five Months</measure>
    <time_frame>5 months</time_frame>
    <description>Maximum weight (pounds) lifted using Cybex weight machine in a single effort(1-RM) for upper extremities (biceps and triceps) and lower extremities quadriceps and hamstrings).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA)</measure>
    <time_frame>5 months</time_frame>
    <description>Lean body mass is expressed in grams as calculated by Hologic DEXA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Bone Mineral Density as Measured by Dual Energy X-ray Absorptiometry (DEXA)</measure>
    <time_frame>5 months</time_frame>
    <description>Bone mineral density measure by measured by dual energy x-ray absorptiometry (DEXA)measured at baseline and a five months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Serum Markers of Bone Turnover.</measure>
    <time_frame>5 months</time_frame>
    <description>Measures of bone turnover markers in serum samples at baseline and at five months.The bone turnover markers analyzed include:
Markers associated with bone breakdown NTX (N-telopeptide) TRAP5b (tartrate-resistant acid phosphatase isoform 5b) Markers associated with bone formation Osteocalcin BAP (bone specific alkaline phosphatase) Regulators of bone formation iPTH (intact parathyroid hormone) increases in response to bone loss Calcitonin inhibits bone formation in response to elevated levels of serum calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9473Changes in Serum Inflammatory Biomarkers and Muscle Inflammatory Cytokines</measure>
    <time_frame>5 months</time_frame>
    <description>Serum inflammatory biomarkers (Interleukin B-1, 2,5,6,7,8,10,12 13, Interferon gamma, GM-CSF, and Tumor Necrosis Factor alpha)as measured by immunoassay at baseline and at five months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly placebo treatment for a duration of 5 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monthly Cycled Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly testosterone treatment for a duration of 5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Weekly im injections of 100 mg testosterone enanthate.</description>
    <arm_group_label>Monthly Cycled Testosterone</arm_group_label>
    <arm_group_label>Continuous Testosterone</arm_group_label>
    <other_name>Testosterone Enanthate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Weekly IM injections of sesame oil.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Monthly Cycled Testosterone</arm_group_label>
    <other_name>Sesame Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Availability of transportation (i.e., subjects must be able to provide their own
             transportation to UTMB).

        Exclusion Criteria:

          -  Medications such as anticoagulants (Coumadin) and glucocorticoids.

          -  History of angina that occurs with exertion or at rest.

          -  History of myocardial infarction within the last 12 months.

          -  Failure to successfully complete an exercise stress test using the Bruce protocol.
             Subjects that demonstrate ≥ 0.1 mV horizontal or downsloping ST segment depression, a
             drop in systolic blood pressure of ≥ 10 mm Hg, and/or frequent or repetitive
             arrhythmias (defined as ≥ 10 PVC/min, or couplets) during the stress test will be
             excluded.

          -  LDL cholesterol above 200 mg/dL.

          -  History of prostatic cancer.

          -  Elevated prostate specific antigen (PSA) above 4.0 µg/L, or severe benign prostatic
             hypertrophy (BPH) by history (frequent urination, reduced stream).

          -  Serum total testosterone concentrations of greater than 500 ng/dL.

          -  Subjects who engage in high intensity, elite training on a regular basis.

          -  Major medical illness such as diabetes, chronic obstructive pulmonary disease, or
             sleep apnea.

          -  Recent history of smoking tobacco.

          -  Hematocrit greater than 51%.

          -  Morbidly obese older men (BMI &gt; 35).

          -  Hypertension: Blood pressure on three consecutive measurements taken at one week
             intervals that has a systolic pressure ≥ 140 or a diastolic blood pressure ≥ 90.
             Subjects will be included if they are on two or less blood pressure medications and
             have a blood pressure below these criteria.

          -  History of hepatitis or a 3-fold elevation of liver function tests (Alk phos, ALT,
             AST).

          -  Bone related disorders such as osteoporosis or parathyroid disease.

          -  DEXA scans revealing lumbar spine T-scores of less than -2.5.

          -  Subjects currently taking anti-bone-resorptive agents such as bisphosphonates,
             parathyroid hormone, or calcitonin.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Urban, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2009</study_first_posted>
  <results_first_submitted>July 19, 2012</results_first_submitted>
  <results_first_submitted_qc>July 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2012</results_first_posted>
  <last_update_submitted>September 4, 2012</last_update_submitted>
  <last_update_submitted_qc>September 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Normal Testosterone</keyword>
  <keyword>Male</keyword>
  <keyword>Aging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject recruitment began in January, 2006 and was closed on December, 2011. Subjects were enrolled at the University of Texas Medical Branch in the Institute for Translational Sciences Clinical Research Center (ITS-CRC).</recruitment_details>
      <pre_assignment_details>Screening was conducted at the ITS-CRC where the subject was consented and screening was conducted to identify eligible subjects.Screening included blood testing and a stress test to determine fitness for physical function testing. Subjects were excluded due to elevated PSA levels, testosterone levels above entry criteria or occult disease.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Weekly placebo treatment for a duration of 5 months.</description>
        </group>
        <group group_id="P2">
          <title>Monthly Cycled Testosterone</title>
          <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
        </group>
        <group group_id="P3">
          <title>Continuous Testosterone</title>
          <description>Weekly testosterone treatment for a duration of 5 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Weekly placebo treatment for a duration of 5 months.</description>
        </group>
        <group group_id="B2">
          <title>Monthly Cycled Testosterone</title>
          <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
        </group>
        <group group_id="B3">
          <title>Continuous Testosterone</title>
          <description>Weekly testosterone treatment for a duration of 5 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.4" spread="3.22"/>
                    <measurement group_id="B2" value="71.6" spread="7.78"/>
                    <measurement group_id="B3" value="73.3" spread="7.54"/>
                    <measurement group_id="B4" value="70.1" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months</title>
        <description>The fractional synthetic rate (FSR) of mixed muscle is calculated by directly measuring the incorporation of L-[ring-13C6]-phenylalanine into protein (%/hr),, using the precursor-product model: FSR = [(EP2 − EP1)/(EM•t)]•60•100, where EP1 and EP2 are the enrichments of bound L-[ring-13C6]-phenylalanine in the first and second muscle biopsies, t is the time interval (min) between biopsies, and EM is the mean L-[ring-13C6]-phenylalanine enrichment in the muscle intracellular pool.</description>
        <time_frame>5 Months</time_frame>
        <population>Subjects who completed the entire treatment protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Monthly Cycled Testosterone</title>
            <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O3">
            <title>Continuous Testosterone</title>
            <description>Weekly testosterone treatment for a duration of 5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months</title>
          <description>The fractional synthetic rate (FSR) of mixed muscle is calculated by directly measuring the incorporation of L-[ring-13C6]-phenylalanine into protein (%/hr),, using the precursor-product model: FSR = [(EP2 − EP1)/(EM•t)]•60•100, where EP1 and EP2 are the enrichments of bound L-[ring-13C6]-phenylalanine in the first and second muscle biopsies, t is the time interval (min) between biopsies, and EM is the mean L-[ring-13C6]-phenylalanine enrichment in the muscle intracellular pool.</description>
          <population>Subjects who completed the entire treatment protocol</population>
          <units>Percent per hour (%/hr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.01"/>
                    <measurement group_id="O2" value="0.06" spread="0.01"/>
                    <measurement group_id="O3" value="0.06" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066" spread="0.020"/>
                    <measurement group_id="O2" value="0.094" spread="0.014"/>
                    <measurement group_id="O3" value="0.101" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Muscle Strength as Measured by Maximal Voluntary Contraction Tests (Arm Curl) at Baseline, One Month, Two Months, Three Months, Four Months, and at Five Months</title>
        <description>Maximum weight (pounds) lifted using Cybex weight machine in a single effort(1-RM) for upper extremities (biceps and triceps) and lower extremities quadriceps and hamstrings).</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Monthly Cycled Testosterone</title>
            <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O3">
            <title>Continuous Testosterone</title>
            <description>Weekly testosterone treatment for a duration of 5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Muscle Strength as Measured by Maximal Voluntary Contraction Tests (Arm Curl) at Baseline, One Month, Two Months, Three Months, Four Months, and at Five Months</title>
          <description>Maximum weight (pounds) lifted using Cybex weight machine in a single effort(1-RM) for upper extremities (biceps and triceps) and lower extremities quadriceps and hamstrings).</description>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arm Curl Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="12"/>
                    <measurement group_id="O2" value="39" spread="10"/>
                    <measurement group_id="O3" value="32" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Extension Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="9"/>
                    <measurement group_id="O2" value="41" spread="14"/>
                    <measurement group_id="O3" value="38" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Curl Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="6"/>
                    <measurement group_id="O2" value="44" spread="7"/>
                    <measurement group_id="O3" value="40" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Extension Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="21"/>
                    <measurement group_id="O2" value="73" spread="15"/>
                    <measurement group_id="O3" value="66" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Curl Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="10"/>
                    <measurement group_id="O2" value="41" spread="10"/>
                    <measurement group_id="O3" value="34" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Curl Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="9"/>
                    <measurement group_id="O2" value="40" spread="10"/>
                    <measurement group_id="O3" value="39" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Curl Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="9"/>
                    <measurement group_id="O2" value="43" spread="11"/>
                    <measurement group_id="O3" value="37" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Curl Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" spread="10"/>
                    <measurement group_id="O2" value="43" spread="13"/>
                    <measurement group_id="O3" value="41" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Curl Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="11"/>
                    <measurement group_id="O2" value="45" spread="13"/>
                    <measurement group_id="O3" value="38" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Extension Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread="7"/>
                    <measurement group_id="O2" value="41" spread="10"/>
                    <measurement group_id="O3" value="37" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Extension Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="8"/>
                    <measurement group_id="O2" value="42" spread="9"/>
                    <measurement group_id="O3" value="44" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Extension Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="8"/>
                    <measurement group_id="O2" value="43" spread="7"/>
                    <measurement group_id="O3" value="44" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Extension Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="8"/>
                    <measurement group_id="O2" value="44" spread="8"/>
                    <measurement group_id="O3" value="44" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Extension Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="8"/>
                    <measurement group_id="O2" value="45" spread="8"/>
                    <measurement group_id="O3" value="45" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Curl Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="7"/>
                    <measurement group_id="O2" value="46" spread="9"/>
                    <measurement group_id="O3" value="41" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Curl Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="11"/>
                    <measurement group_id="O2" value="47" spread="9"/>
                    <measurement group_id="O3" value="48" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Curl Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="7"/>
                    <measurement group_id="O2" value="43" spread="20"/>
                    <measurement group_id="O3" value="48" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Curl Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="7"/>
                    <measurement group_id="O2" value="50" spread="10"/>
                    <measurement group_id="O3" value="50" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Curl Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="10"/>
                    <measurement group_id="O2" value="50" spread="11"/>
                    <measurement group_id="O3" value="51" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Extension Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="13"/>
                    <measurement group_id="O2" value="73" spread="10"/>
                    <measurement group_id="O3" value="67" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Extension Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" spread="14"/>
                    <measurement group_id="O2" value="77" spread="16"/>
                    <measurement group_id="O3" value="78" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Extension Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="13"/>
                    <measurement group_id="O2" value="80" spread="14"/>
                    <measurement group_id="O3" value="76" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Extensuion Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="14"/>
                    <measurement group_id="O2" value="79" spread="16"/>
                    <measurement group_id="O3" value="82" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leg Extension Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="14"/>
                    <measurement group_id="O2" value="85" spread="19"/>
                    <measurement group_id="O3" value="83" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA)</title>
        <description>Lean body mass is expressed in grams as calculated by Hologic DEXA.</description>
        <time_frame>5 months</time_frame>
        <population>All subjects who successfully completed the five month protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Monthly Cycled Testosterone</title>
            <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O3">
            <title>Continuous Testosterone</title>
            <description>Weekly testosterone treatment for a duration of 5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA)</title>
          <description>Lean body mass is expressed in grams as calculated by Hologic DEXA.</description>
          <population>All subjects who successfully completed the five month protocol.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lean Body Mass Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62344" spread="10368"/>
                    <measurement group_id="O2" value="57101" spread="6671.5"/>
                    <measurement group_id="O3" value="57746" spread="6485.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lean Body Mass Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62994.7" spread="10308.8"/>
                    <measurement group_id="O2" value="59155.4" spread="6890.9"/>
                    <measurement group_id="O3" value="60469.3" spread="6555.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lean Body Mass Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62038.7" spread="10556.5"/>
                    <measurement group_id="O2" value="56787.8" spread="6444.16"/>
                    <measurement group_id="O3" value="62680.1" spread="4034.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lean Body Mass Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62256.5" spread="9881.65"/>
                    <measurement group_id="O2" value="59186" spread="6267.63"/>
                    <measurement group_id="O3" value="61167.3" spread="7530.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lean Body Mass Month 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62755.4" spread="10756.2"/>
                    <measurement group_id="O2" value="59838.6" spread="7010.73"/>
                    <measurement group_id="O3" value="61436.6" spread="6997.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lean Body Month 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61250.6" spread="11283.3"/>
                    <measurement group_id="O2" value="58846.9" spread="6995.48"/>
                    <measurement group_id="O3" value="60871.4" spread="6840.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Bone Mineral Density as Measured by Dual Energy X-ray Absorptiometry (DEXA)</title>
        <description>Bone mineral density measure by measured by dual energy x-ray absorptiometry (DEXA)measured at baseline and a five months</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Monthly Cycled Testosterone</title>
            <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O3">
            <title>Continuous Testosterone</title>
            <description>Weekly testosterone treatment for a duration of 5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Bone Mineral Density as Measured by Dual Energy X-ray Absorptiometry (DEXA)</title>
          <description>Bone mineral density measure by measured by dual energy x-ray absorptiometry (DEXA)measured at baseline and a five months</description>
          <units>gm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.04"/>
                    <measurement group_id="O2" value="1.07" spread="0.05"/>
                    <measurement group_id="O3" value="1.12" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.07"/>
                    <measurement group_id="O2" value="1.05" spread="0.05"/>
                    <measurement group_id="O3" value="1.14" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.07"/>
                    <measurement group_id="O2" value="1.00" spread="0.05"/>
                    <measurement group_id="O3" value="1.16" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar Spine Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.07"/>
                    <measurement group_id="O2" value="1.00" spread="0.05"/>
                    <measurement group_id="O3" value="1.19" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvis baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.16"/>
                    <measurement group_id="O2" value="1.15" spread="0.04"/>
                    <measurement group_id="O3" value="1.27" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvis Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.14"/>
                    <measurement group_id="O2" value="1.14" spread="0.04"/>
                    <measurement group_id="O3" value="1.28" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forearm Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.02"/>
                    <measurement group_id="O2" value="0.59" spread="0.02"/>
                    <measurement group_id="O3" value="0.61" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forearm Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.02"/>
                    <measurement group_id="O2" value="0.59" spread="0.03"/>
                    <measurement group_id="O3" value="0.62" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Serum Markers of Bone Turnover.</title>
        <description>Measures of bone turnover markers in serum samples at baseline and at five months.The bone turnover markers analyzed include:
Markers associated with bone breakdown NTX (N-telopeptide) TRAP5b (tartrate-resistant acid phosphatase isoform 5b) Markers associated with bone formation Osteocalcin BAP (bone specific alkaline phosphatase) Regulators of bone formation iPTH (intact parathyroid hormone) increases in response to bone loss Calcitonin inhibits bone formation in response to elevated levels of serum calcium</description>
        <time_frame>5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Monthly Cycled Testosterone</title>
            <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O3">
            <title>Continuous Testosterone</title>
            <description>Weekly testosterone treatment for a duration of 5 months</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Markers of Bone Turnover.</title>
          <description>Measures of bone turnover markers in serum samples at baseline and at five months.The bone turnover markers analyzed include:
Markers associated with bone breakdown NTX (N-telopeptide) TRAP5b (tartrate-resistant acid phosphatase isoform 5b) Markers associated with bone formation Osteocalcin BAP (bone specific alkaline phosphatase) Regulators of bone formation iPTH (intact parathyroid hormone) increases in response to bone loss Calcitonin inhibits bone formation in response to elevated levels of serum calcium</description>
          <units>nM BCE (Bone Collagen Equivalents)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NTX Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="1.3"/>
                    <measurement group_id="O2" value="14" spread="1.4"/>
                    <measurement group_id="O3" value="15" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTX Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="1.1"/>
                    <measurement group_id="O2" value="11" spread="0.7"/>
                    <measurement group_id="O3" value="11" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAP5b Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.6"/>
                    <measurement group_id="O2" value="2" spread="0.6"/>
                    <measurement group_id="O3" value="2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAP5b Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.6"/>
                    <measurement group_id="O2" value="2" spread="0.6"/>
                    <measurement group_id="O3" value="1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="0.2"/>
                    <measurement group_id="O2" value="8" spread="0.6"/>
                    <measurement group_id="O3" value="9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteocalcin Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="0.5"/>
                    <measurement group_id="O2" value="8" spread="0.5"/>
                    <measurement group_id="O3" value="7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAP Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="1.5"/>
                    <measurement group_id="O2" value="20" spread="2.3"/>
                    <measurement group_id="O3" value="17" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BAP Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="1.3"/>
                    <measurement group_id="O2" value="19" spread="1.9"/>
                    <measurement group_id="O3" value="15" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iPTH Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" spread=".3"/>
                    <measurement group_id="O2" value="37" spread="6"/>
                    <measurement group_id="O3" value="53" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>iPTH Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="7"/>
                    <measurement group_id="O2" value="28" spread="3"/>
                    <measurement group_id="O3" value="60" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcitonin Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.4"/>
                    <measurement group_id="O2" value="4" spread="0.6"/>
                    <measurement group_id="O3" value="4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcitonin Five months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.4"/>
                    <measurement group_id="O2" value="4" spread="0.5"/>
                    <measurement group_id="O3" value="3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>9473Changes in Serum Inflammatory Biomarkers and Muscle Inflammatory Cytokines</title>
        <description>Serum inflammatory biomarkers (Interleukin B-1, 2,5,6,7,8,10,12 13, Interferon gamma, GM-CSF, and Tumor Necrosis Factor alpha)as measured by immunoassay at baseline and at five months</description>
        <time_frame>5 months</time_frame>
        <population>All subjects who completed the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Monthly Cycled Testosterone</title>
            <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
          </group>
          <group group_id="O3">
            <title>Continuous Testosterone</title>
            <description>Weekly testosterone treatment for a duration of 5 months</description>
          </group>
        </group_list>
        <measure>
          <title>9473Changes in Serum Inflammatory Biomarkers and Muscle Inflammatory Cytokines</title>
          <description>Serum inflammatory biomarkers (Interleukin B-1, 2,5,6,7,8,10,12 13, Interferon gamma, GM-CSF, and Tumor Necrosis Factor alpha)as measured by immunoassay at baseline and at five months</description>
          <population>All subjects who completed the protocol.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-B1 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.1"/>
                    <measurement group_id="O2" value="0.475" spread="0.76767"/>
                    <measurement group_id="O3" value="1.44143" spread="2.04769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-B1 Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20833" spread="0.22221"/>
                    <measurement group_id="O2" value="3.19" spread="3.24643"/>
                    <measurement group_id="O3" value="2.538" spread="3.33404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="1.18655"/>
                    <measurement group_id="O2" value="3.19" spread="3.24643"/>
                    <measurement group_id="O3" value="2.538" spread="3.33404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="1.99008"/>
                    <measurement group_id="O2" value="1.45333" spread="0.94076"/>
                    <measurement group_id="O3" value="3.862" spread="5.90798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.71529"/>
                    <measurement group_id="O2" value="0.79" spread="0.76783"/>
                    <measurement group_id="O3" value="1.41875" spread="1.92013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5 Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.705" spread="1.32898"/>
                    <measurement group_id="O2" value="0.32286" spread="0.30065"/>
                    <measurement group_id="O3" value="1.94125" spread="3.46852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68375" spread="6.78293"/>
                    <measurement group_id="O2" value="4.90857" spread="6.43277"/>
                    <measurement group_id="O3" value="10.4025" spread="20.5897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 Five months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="6.0643"/>
                    <measurement group_id="O2" value="6.487" spread="178.673"/>
                    <measurement group_id="O3" value="13.89" spread="28.8691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.78" spread="10.4076"/>
                    <measurement group_id="O2" value="11.9688" spread="16.2135"/>
                    <measurement group_id="O3" value="5.19875" spread="2.84198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7 Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.68" spread="10.898"/>
                    <measurement group_id="O2" value="23.1888" spread="52.3705"/>
                    <measurement group_id="O3" value="16.2763" spread="19.6011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5575" spread="2.67011"/>
                    <measurement group_id="O2" value="6.66375" spread="4.50933"/>
                    <measurement group_id="O3" value="8.45625" spread="11.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 Five months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3225" spread="2.0872"/>
                    <measurement group_id="O2" value="4.06286" spread="1.76795"/>
                    <measurement group_id="O3" value="11.8025" spread="20.6936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6363" spread="41.8883"/>
                    <measurement group_id="O2" value="11.2588" spread="8.19838"/>
                    <measurement group_id="O3" value="109.446" spread="240.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4525" spread="41.4135"/>
                    <measurement group_id="O2" value="8.34143" spread="3.65748"/>
                    <measurement group_id="O3" value="135.64" spread="265.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.075" spread="12.3805"/>
                    <measurement group_id="O2" value="4.242" spread="4.07052"/>
                    <measurement group_id="O3" value="35.3583" spread="56.0444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12 Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.902" spread="17.4143"/>
                    <measurement group_id="O2" value="2.66" spread="3.7993"/>
                    <measurement group_id="O3" value="58.4217" spread="86.8424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13 baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.045" spread="51.9229"/>
                    <measurement group_id="O2" value="23.33" spread="48.7029"/>
                    <measurement group_id="O3" value="60.2125" spread="102.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13 Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.465" spread="61.0587"/>
                    <measurement group_id="O2" value="12.72" spread="17.2687"/>
                    <measurement group_id="O3" value="73.674" spread="148.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.115" spread="15.7219"/>
                    <measurement group_id="O2" value="4.58" spread="7.63943"/>
                    <measurement group_id="O3" value="23.425" spread="28.8768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN gamma Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.05" spread="68.7309"/>
                    <measurement group_id="O2" value="1.758" spread="1.98486"/>
                    <measurement group_id="O3" value="36.822" spread="69.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52429" spread="2.46286"/>
                    <measurement group_id="O2" value="2.4" spread="2.58639"/>
                    <measurement group_id="O3" value="7.94875" spread="16.6389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27857" spread="3.19199"/>
                    <measurement group_id="O2" value="1.312" spread="0.88649"/>
                    <measurement group_id="O3" value="14.965" spread="37.1713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0175" spread="4.60793"/>
                    <measurement group_id="O2" value="10.0863" spread="4.51058"/>
                    <measurement group_id="O3" value="13.215" spread="10.1743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF alpha Five Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" spread="3.95778"/>
                    <measurement group_id="O2" value="8.1529" spread="3.70965"/>
                    <measurement group_id="O3" value="15.4138" spread="13.0438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Weekly placebo treatment for a duration of 5 months.</description>
        </group>
        <group group_id="E2">
          <title>Monthly Cycled Testosterone</title>
          <description>A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.</description>
        </group>
        <group group_id="E3">
          <title>Continuous Testosterone</title>
          <description>Weekly testosterone treatment for a duration of 5 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Saphenous vein clot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Randall Urban, M.D., Professor of Medicine</name_or_title>
      <organization>The University of Texas Medical Branch at Galveston</organization>
      <phone>409- 772-1176</phone>
      <email>rurban@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

